Literature DB >> 29269428

Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?

Kwok-Chiu Chang1, Wing-Wai Yew2, Ying Zhang3.   

Abstract

Entities:  

Keywords:  drug resistant; pyrazinamide; tuberculosis

Mesh：

Substances：

Year:  2017        PMID： 29269428      PMCID： PMC5740308          DOI： 10.1128/AAC.01907-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  29 in total

1.  Reaching consensus on drug resistance conferring mutations.

Authors:  Daniela M Cirillo; Paolo Miotto; Elisa Tagliani
Journal:  Int J Mycobacteriol       Date:  2016-11-15

2.  pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada.

Authors:  S J Cheng; L Thibert; T Sanchez; L Heifets; Y Zhang
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 3.  The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Gary Maartens; Kelly E Dooley; Ruth McNerney; Megan Murray; Jennifer Furin; Edward A Nardell; Leslie London; Erica Lessem; Grant Theron; Paul van Helden; Stefan Niemann; Matthias Merker; David Dowdy; Annelies Van Rie; Gilman K H Siu; Jotam G Pasipanodya; Camilla Rodrigues; Taane G Clark; Frik A Sirgel; Aliasgar Esmail; Hsien-Ho Lin; Sachin R Atre; H Simon Schaaf; Kwok Chiu Chang; Christoph Lange; Payam Nahid; Zarir F Udwadia; C Robert Horsburgh; Gavin J Churchyard; Dick Menzies; Anneke C Hesseling; Eric Nuermberger; Helen McIlleron; Kevin P Fennelly; Eric Goemaere; Ernesto Jaramillo; Marcus Low; Carolina Morán Jara; Nesri Padayatchi; Robin M Warren
Journal:  Lancet Respir Med       Date:  2017-03-15       Impact factor: 30.700

4.  Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.

Authors:  G P Morlock; J T Crawford; W R Butler; S E Brim; D Sikes; G H Mazurek; C L Woodley; R C Cooksey
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.

Authors:  Russell R Kempker; M Tobias Heinrichs; Ketino Nikolaishvili; Irina Sabulua; Nino Bablishvili; Shota Gogishvili; Zaza Avaliani; Nestani Tukvadze; Brent Little; Adam Bernheim; Timothy D Read; Jeannette Guarner; Hartmut Derendorf; Charles A Peloquin; Henry M Blumberg; Sergo Vashakidze
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

6.  Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis.

Authors:  N Lemaitre; I Callebaut; F Frenois; V Jarlier; W Sougakoff
Journal:  Biochem J       Date:  2001-02-01       Impact factor: 3.857

7.  Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Sami O Simons; Jakko van Ingen; Tridia van der Laan; Arnout Mulder; P N Richard Dekhuijzen; Martin J Boeree; Dick van Soolingen
Journal:  J Clin Microbiol       Date:  2011-11-16       Impact factor: 5.948

8.  Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.

Authors:  Zahoor Ahmad; Sandeep Tyagi; Austin Minkowski; Charles A Peloquin; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

9.  Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis.

Authors:  Shuo Zhang; Jiazhen Chen; Wanliang Shi; Peng Cui; Jia Zhang; Sanghyun Cho; Wenhong Zhang; Ying Zhang
Journal:  Emerg Microbes Infect       Date:  2017-02-15       Impact factor: 7.163

10.  A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis.

Authors:  Mariam O Fofana; Sourya Shrestha; Gwenan M Knight; Ted Cohen; Richard G White; Frank Cobelens; David W Dowdy
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191
View more
  2 in total

1.  Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of pncA PCR Sequencing.

Authors:  Kingsley King-Gee Tam; Kenneth Siu-Sing Leung; Gilman Kit-Hang Siu; Kwok-Chiu Chang; Samson Sai-Yin Wong; Pak-Leung Ho; Eunice Ka-Chun Leung; Wing-Cheong Yam
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

2.  Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"

Authors:  Charles A Peloquin; Russell R Kempker
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.